MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting

Rockville, MD, April 29, 2020 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced three clinical presentations at the American Society of Clinical Oncology (ASCO) upcoming ASCO20 Virtual Scientific Program to be held May 29-31, 2020.

ASCO Virtual Presentations

Title: A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms
Authors: Jason J. Luke, et al.
Session: Developmental Therapeutics—Immunotherapy
Session Type: Oral Abstract Session
Abstract: 3004

Title: Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors
Authors: John D. Powderly, et al.
Session: Developmental Therapeutics—Immunotherapy
Session Type: Poster Abstract Session
Abstract: 3071
Poster: 135

Title: SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC)
Authors: Santiago Escrivá, et al.
Session: Breast Cancer—Metastatic
Session Type: Poster Abstract Session
Abstract: 1040
Poster: 125

Presentations will be available for on-demand viewing online at https://meetings.asco.org/am/virtual-program beginning on May 29, 2020 at 8:00 a.m. ET.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.

Anna Krassowska, Ph.D., Vice President, Investor Relations & Corporate Communications
Jim Karrels, Senior Vice President, CFO
1-301-251-5172, info@macrogenics.com